Omeros Corporation (OMER)
Nasdaq · Healthcare · Biotechnology
$18.90+1.56%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $1.4B
- P/E (trailing)
- 15.5
- Forward P/E
- 15.4
- 52-week range
- $4.06 – $21.24
- 52-week change
- +319.14%
- EPS (trailing)
- $1.22
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 12, 2026
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms.
Headquarters: Seattle, United States · 175 employees · omeros.com